	US 12,228,572 B2
	Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells
Guoxin Liang, Shenyang (CN); and Hong Shang, Shenyang (CN)
Assigned to THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY, Shenyang (CN)
Appl. No. 18/292,949
Filed by THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY, Shenyang (CN)
PCT Filed Sep. 30, 2021, PCT No. PCT/CN2021/122082 § 371(c)(1), (2) Date Jan. 29, 2024, PCT Pub. No. WO2023/004994, PCT Pub. Date Feb. 2, 2023.
Claims priority of application No. 202110855712.1 (CN), filed on Jul. 28, 2021.
Prior Publication US 2024/0264171 A1, Aug. 8, 2024
Int. Cl. G01N 33/569 (2006.01); A61P 31/18 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/56988 (2013.01) [A61P 31/18 (2018.01); C12Y 207/11021 (2013.01); G01N 33/6893 (2013.01); C12N 2740/16011 (2013.01); G01N 2333/16 (2013.01); G01N 2333/912 (2013.01)]

2 Claims

1. An in vitro method of enhancing an expression of a PLK3 protein in an HIV-infected cell comprising the step of transfecting the HIV-infected cell with a PLK3 protein expression vector; wherein the PLK3 protein is a PLK3-201 protein, and the PLK3-201 protein has the amino acid sequence shown in SEQ ID NO: 1.